tbuckley/cabot-search huggingface dataset:
Hepatic arterial embolization adopting polyvinyl alcohol microspheres preloaded with irinotecan versus systemic chemotherapy for hepatic metastases from colorectal cancer: A phase III clinical research trial of activity and quality of life.
Authors: Giammaria Fiorentini, Camillo Aliberti, Massimo Tilli, Paolo Coschiera, Andrea Mambrini, Paolo Giordani, Paolo Alessandroni, Giorgio Benea
Journal: Journal of Clinical Oncology (2012)

587 Background: Patients with liver metastases (LM) from colorectal cancer (CRC) have a severe prognosis with the 5-year survival of 25% after radical resection; for not operable metastases the survival is poor. Embolization using polyvinil alcohol microspheres loaded with IRI 200 mgr (D) is a feasible procedure. FOLFIRI (CT) is active for the treatment of CRC. We planned this phase III study to assess survival as primary endpoint to increase median survival (MS) by 40% at 2-y (HR=0.72). QoL, responses, progression-free survival (PFS) and safety are secondary endpoints. Methods: Between December 2006 and December 2008, 74 pts were randomized, 37 patients to D and 37 to CT. Two D patients had early progression and two CT patients refused. 70 cycles of D were administered in 35 pts, with a dose intensity (DI) of 99%, and 292 CT cycles were delivered to 35 pts with a DI of 90%. Results: At a median follow up of 30 months ( 18-42) we reported (D vs CT): MS 48% vs 28%, Response Rate 70% vs 20%, Acute Toxicity 70% vs 20%, Late Toxicity 20% vs 80%, QoL improvement 65% vs 25%, Costs for each pt: 7,000 vs 24,000 euro. Conclusions: D increased the 30-Months MS difference of 20% compared to CT. D improved responses, Performance Status and reduced costs. D reported higher immediate toxicity, mainly fever and abdominal pain, than CT. Late toxicity, mainly haematological, diarrhoea, asthenia and alopecia, was more common in CT. We conclude that D compared to CT increases survival and palliative results in patients with LM from CRC.
P21.07 Temozolomide for Progressive Pituitary Adenomas Refractory to Surgery and Radiation: A Case Series
Authors: J. T. Jordan, J. J. Miller, T. Cushing, W. T. Curry, H. A. Shih, L. Nachtigall, J. Loeffler, J. Dietrich
Journal: Neuro-Oncology (2016)

AbstractIntroduction:Treatment of aggressive pituitary adenomas typically involves a multimodality approach based on histopathological features and may include pharmacotherapy, surgery and radiation therapy. In cases of treatment-refractory tumor progression, chemotherapy may be considered. However, no standard chemotherapeutic regimen has been established. Anecdotal reports suggest that temozolomide may have a beneficial role in a subset of cases.Materials and Methods:In this case series and institutional experience we report the outcome and unique clinical characteristics of seven patients with aggressive pituitary tumors treated with temozolomide given at various dose regimens.Results:Tumor pathology included somatotrope (n=1), corticotrope (n=3), and lactotrope (n=3) tumors. Four of the seven patients had at least two prior resections, and all had prior radiation and surgery before treatment with temozolomide was considered. Notably, all patients showed response to therapy, defined as either stable disease (43%) or partial response (57%), using standard tumor response assessment parameters. Excluding the two patients who remain on therapy to date, total duration of therapeutic benefit ranged between 5–15 months. Three patients showed radiographic and clinical benefit beyond one year.Conclusions:Our data suggest that temozolomide may have an important role in the management of aggressive functioning pituitary tumors that are resistant to standard therapies, and that optimization of therapy with temozolomide may involve individualized regimens. Future prospective clinical trials should be considered.
Defining An Optimal Therapeutic Range for Busulfan (Bu) Administered with Pre-and Post-Transplant Cyclophosphamide (Cy) In HLA-Matched Related and Unrelated Bone Marrow Transplantation (BMT).
Authors: Lindsey R Lombardi, Marianna Zahurak, Nadira Durakovic, Jeanne Kowalski, Richard J. Jones, Leo Luznik
Journal: Blood (2010)
Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Sergio Cortelazzo, Gianluca Gaidano, Michael Mian, Annarita Conconi, Andrea Rossi, Maria E. Cabrera, Massimo Federico, Monica Bellei, Stefano Magrini, Maurizio Martelli, Henry Gomez, Armando Lopez-Guillermo, Enrico M. Pogliani, Fausto Rossini, Mario Busetto, Carlo Visco, Richard Tsang, Emanuele Zucca, Alessandro Rambaldi, Franco Cavalli
Journal: Blood (2007)
Journal retracts Chinese paper because transplanted livers couldn’t be traced
Authors: Owen Dyer
Journal: BMJ (2017)

A Chinese study of liver transplantation has been retracted by the journal Liver International after its authors failed to persuade editors that 564 livers grafted in the course of the research were not taken from executed prisoners.

Prompted by a letter from an Australian academic that explained the statistical improbability of the livers having been freely donated, editors at the journal sought reassurance from the study’s authors that the organs did not come from prisoners. The authors reiterated a claim made in the article that “all organs were procured from donors after cardiac death and no allografts obtained from executed prisoners were used.”

But when …
CD49d Prevails over the Novel Recurrent Mutations As Independent Prognosticator of Overall Survival in Chronic Lymphocytic Leukemia
Authors: Michele Dal Bo, Pietro Bulian, Riccardo Bomben, Antonella Zucchetto, Francesca Rossi, Federico Pozzo, Tamara Bittolo, Paola Nanni, Ilaria Cattarossi, Eva Zaina, Hillarj Chivilò, Massimo Degan, Francesco Zaja, Gabriele Pozzato, Annalisa Chiarenza, Francesco Di Raimondo, Giovanni Del Poeta, Davide Rossi, Gianluca Gaidano, Valter Gattei
Journal: Blood (2015)
Availability of tumour gene expression data facilitates clinical decision-making for patients with advanced cancers
Authors: J. Laskin, C. Ho, Y. Shen, M. Jones, K.A. Gelmon, H. Lim, D.J. Renouf, S. Yip, A. Tinker, K. Khoo, C. Lohrisch, S. Chia, B. Deol, K. Schrader, Y. Ma, R. Moore, A. Mungall, S. Jones, M. Marra
Journal: Annals of Oncology (2016)
Sickle Cell Trait and Interpretation of Hemoglobin A<sub>1c</sub> Levels
Authors: Anthony J. Bleyer, Joseph A. Aloi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.
Authors: Valeria R. Fantin, Andrey Loboda, Jennifer A. Roth, Cloud Paweletz, Sophia Randolph, Jacqueline W. Pierce, Elizabeth A. Harrington, Ronald C. Hendrickson, John F. Reilly, Christopher Ware, Marshall E. Kadin, Madeleine Duvic, Stanley R. Frankel, Victoria M. Richon
Journal: Blood (2006)
Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH®, MABCAMPATH®) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL).
Authors: Tadeusz Robak, Anna Dmoszynska, Raouf Fetni, Ying Wang, Malika Belkacz, Cynthia Sirard, Mark Goldberg, Aleksander Skotnicki, Jiri Mayer, Peter Hillmen
Journal: Blood (2006)
SNP-a Karyotyping Provides a Clonal Molecular Marker and Is Associated with a High Incidence of Segmental Uniparental Disomy in Patients with CMML
Authors: Michael McDevitt, Andrew Jeffrey Dunbar, Christine O’Keefe, Hideki Makishima, Ramon V. Tiu, Lukasz Gondek, Judith E. Karp, Xiao-Fei Wang, Mark J. Levis, Jaroslaw Maciejewski
Journal: Blood (2008)
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
Authors: Pin Zhang, Tao Sun, Qingyuan Zhang, Zhongyu Yuan, Zefei Jiang, Xiao Jia Wang, Shude Cui, Yuee Teng, Xi-Chun Hu, Junlan Yang, Hongming Pan, Zhongsheng Tong, Huiping Li, Qiang Yao, Yongsheng Wang, Yongmei Yin, Ping Sun, Hong Zheng, Jing Cheng, Jinsong Lu, Baochun Zhang, Cuizhi Geng, Jian Liu, Roujun Peng, Min Yan, Shaohua Zhang, Jian Huang, Li Tang, Rongguo Qiu, Binghe Xu
Journal: The Lancet Oncology (2017)
Short-course radiation for palliation of squamous cell carcinoma of an unknown primary of the head and neck.
Authors: Shayna Eliana Rich, William M. Mendenhall
Journal: Journal of Clinical Oncology (2016)

62 Background: The purpose of this study was to examine the treatment patterns used for palliative radiotherapy for squamous cell carcinoma of an unknown primary of the head and neck and to compare the acute toxicity and tumor response for these patients for the most common dose-fractionation regimens. Methods: Patients with biopsy-proven squamous cell carcinoma of an unknown primary with cervical lymphadenopathy were included who were treated with radiation therapy with palliative intent at a single institution between 1966 and 2015 (N = 45). Chart abstraction was performed on the radiation therapy records and follow-up visit notes. Results: Most patients presented with N3 disease (32/45, 71%), with symptoms of pain (19/45, 42%), or with difficulty swallowing (12/45, 27%). Patients were most commonly treated with 20 Gy in 2 fractions (13/45, 29%) or 30 Gy in 10 fractions (13/45, 29%). Toxicity was mild regardless of dose-fractionation, with only 6 patients experiencing dysphagia and 1 having a pulmonary embolus. Most patients had a partial nodal response during the radiation course (25/45, 56%), and partial symptom response by the first followup (17/33, 52%). Results were similar for 20 Gy and 30 Gy courses. Median survival was approximately 5 months and did not differ by radiation course. Conclusions: Patients treated with dose-fractionations of 20 Gy in 2 weekly treatments or 30 Gy in 10 fractions had minimal toxicity. Most patients had an excellent response in nodal size during radiation and nearly all had symptomatic response within the first month of follow. Patients with advanced disease of the head and neck may have a surprising durability of response with even a short course of palliative radiation therapy.
Preventing weight gain in all adults may cut diabetes by a fifth, study shows
Authors: Susan Mayor
Journal: BMJ (2017)

Public health strategies aiming to prevent adult weight gain in the whole population could be twice as effective in reducing the incidence of type 2 diabetes as weight loss strategies targeting only obese people, analysis of a large population based follow-up study has found.1

The link between excess weight and type 2 diabetes is well established, and encouraging overweight people to lose weight is a key part of diabetes prevention in clinical practice. But the effectiveness of trying to prevent weight gain throughout the whole adult population as part of efforts to reduce diabetes has not been …
Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma
Authors: Xiao Ni, Jeffrey L. Jorgensen, Meghali Goswami, Pramoda Challagundla, William K Decker, Youn H. Kim, Madeleine Duvic
Journal: Blood (2011)
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
Authors: R. Komaki, G. R. Blumenschein, I. I. Wistuba, J. J. Lee, P. Allen, X. Wei, J. Welsh, M. O'Reilly, R. S. Herbst, X. Tang, R. Meyn, D. Liu, W. K. Hong
Journal: Journal of Clinical Oncology (2011)

7020 Background: Majority of non-small cell lung cancer (NSCLC) overexpress EGFR. Our prospective phase II trial investigated EGFR-TKI (erlotinib) as a radiosensitizer for inoperable stage III NSCLC patients (pts) who also received standard chemoradiotherapy (ChT/RT). Methods: 48 stage III NSCLC pts were enrolled from 3/2008 through 6/2010. ChT/RT was given every Monday followed by erlotinib/RT on Tuesday-Friday and erlotinib alone over the weekend. RT (63 Gy in 35 fractions) with weekly paclitaxel (45mg/m2)/carboplatin (AUC=2) and erlotinib (150 mg p.o. daily except on the day of chemotherapy) were given for 7 weeks. After one month break, pts received two cycles consolidation of paclitaxel (AUC=6) and carboplatin (200mg/m2). EGFR mutation analysis was performed for 41 pts. The response was evaluated by CT scan three months after completion of ChT/RT based on RECIST criteria. Fisher's exact and Kaplan-Meier's tests were used for the statistical analysis. Results: 46 pts completed the entire treatment are evaluable for response. All had PS KPS ≥80, 17 (37%) were female, 23 adenocarcinoma, and 87% former or current smokers, with median age 63 year-old (range: 46-81). Responses showed 14 (30%) CR, 23 (50%) PR and 9 (20%) stable or progressive disease. Five in 41 pts (12%) had EGFR mutation (EGFR-M), all adenocarcinoma with 2 females, compared to none of squamous histology (p=0.05). CR and non-CR were 3 and 2 in the EGFR-M group compared to 11 and 25 in the EGFR-wild group (p=0.32), respectively. The median OS and PFS were 25.8 mons & 13.6 mons, respectively. 1-year & 2-year OS were 84% & 75% and PFS 54% & 32%, respectively. Toxicity showed 2 grade 3 acne, 1 Grade 3 esophagitis, 3 Grade 3 pneumonitis and no Grade 4-5. Conclusions: This prospective phase II clinical study demonstrated an excellent 1-year OS 84 % and median OS 25.8 mons. All EGFR-M were seen in adenocarcinomas. Erlotinib demonstrated a radiosensitization effect.
Key concerns and symptoms of patients undergoing second- and third-line treatment for non-small cell lung cancer: Findings from a patient interview study.
Authors: Susan Magasi, Karen Kaiser, Rajiv Mallick, David Cella
Journal: Journal of Clinical Oncology (2012)

63 Background: Understanding key concerns and symptoms of patients undergoing cancer treatment is important for characterizing drug treatment benefit as well as developing appropriate psychosocial support interventions. The purpose of this interview study of patients undergoing second and third line therapy for non-small cell lung cancer (NSCLC) was to characterize their physiological, especially pulmonary, symptoms, functional impacts, emotional distress, health-related quality of life (HRQOL), and coping strategies. Methods: Semi-structured thematic interviews with 20 patients in second and third line treatment for advanced NSCLC. Interviews included open elicitation of NSCLC symptoms, their functional impact, and coping strategies. Results: Mean age was 62 years (range 30-79); 80% of patients had non-squamous histology, and 25% had co-morbid COPD. Patients described a range of core symptom experiences, severity, functional impacts, and coping strategies. Shortness of breath (reported by 16/20, 13/20 rated as very important), cough (reported by 14/20, 10/20 rated as very important), and chest tightness (reported by 15/20, 9/20 rated as very important) emerged as key pulmonary symptoms. Ninety percent (18/20) of patients reported tiredness or fatigue, mostly as “very important.” A quarter (5/20) of the patients reported having no pulmonary symptoms. The symptom importance ratings were influenced by the symptom’s impact on valued roles and responsibilities. Patients reported diverse coping strategies including breaking down activities into manageable tasks, priority setting, using physical assistance, emotional support, and adoption of diet/exercise changes. Conclusions: Findings from this interview study of patients receiving second and third line treatment for advanced NSCLC reveal the importance and relevance of core physiological, especially pulmonary, symptoms in characterizing the benefits of drug therapies. These findings offer insights to the patient education and psychosocial interventions that are likely to enhance patients’ HRQOL.
Clinical and Biological EFFECTS of 5-Azacitidine FIVE Days/Monthly Schedule IN Symptomatic LOW-RISK (IPSS: 0-1) Myelodisplastic Patient.
Authors: Carla Filí, Marco Gobbi, Giovanni Martinelli, Carlo Finelli, Ilaria Iacobucci, Emanuela Ottaviani, Lucio Cocco, Matilde Y Follo, Anna Candoni, Erica Simeone, Maurizio Miglino, Francesco Lauria, Monica Bocchia, Marzia Defina, Cristina Clissa, Cristina Skert, Cesare Bergonzi, Michele Malagola, Aldo M. Roccaro, Annalisa Peli, Alessandro Turra, Chiara Colombi, Domenico Russo
Journal: Blood (2009)
Patient-reported outcomes following preoperative chemoradiotherapy for rectal cancer: A prospective multicenter observational study
Authors: P. Salvatore, P. Del Bianco, S. Serpentini, P. Toppan, A. DePaoli, C. Capirci, F. Efficace, D. Cuicchi, A. Amato, D. Nitti
Journal: Journal of Clinical Oncology (2008)

4099 Background: Little evidence is available on patient reported outcomes (PROs) following preoperative chemoradiotherapy (CRT) for rectal cancer. Methods: 151 patients with mid-low rectal cancer were enrolled in this study. PROs were evaluated with methodologically sound robust measures. Quality of life was measured with the EORTC QLQ-C30 and its colorectal cancer module (QLQ-CR38). Psychological aspects, fecal incontinence and functional outcomes were measured respectively with the Psychological Well-Being Index (PGWBI) and the Fecal Incontinence Score (FIS) questionnaires. All self-reported questionnaires were completed before CRT (baseline, t0), 3 weeks after the completion of CRT (t1), and then at 6 (t2) and 12 months (t3) after surgery. Socio-demographic and clinical data were also collected. Comparisons were made by repeated measures analysis of variance for each PRO domain. Analysis was planned a priori on most relevant outcomes. A p-value <.01 was considered statistically significant. Results: Compliance was 100%, 94%, 84%, and 75% at t0, t1, t2 and t3, respectively. Physical, role and social functioning scales had a significant worse decline from t0 to t1 and then remained stable at t2 and t3. Male and female sexual problems, measured with the QLQ-CR38, deteriorated significantly over time and also showed clinically meaningful worse scores from baseline to t1, t2 and t3. Emotional functioning and future perspective showed a significant improvement. Similarly, the PGWBI showed an improvement over time of anxiety, depressed mood, and well being. Compared to the baseline and t1, FIS scores were found to be worse at t2 and t3 assessment. Conclusions: While physically-related aspects, therapy side effects and fecal incontinence were impaired over time, there was an indication towards improved psychological outcomes No significant financial relationships to disclose.
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.
Authors: Enrico Tiacci, Gianluca Schiavoni, Maria Paola Martelli, Emanuela Boveri, Roberta Pacini, Alessia Tabarrini, Silvia Zibellini, Alessia Santi, Valentina Pettirossi, Elisabetta Fortini, Stefano Ascani, Luca Arcaini, Giorgio Inghirami, Marco Paulli, Brunangelo Falini
Journal: Blood (2012)
ACTR-47. TPI 287, A BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: RESULTS FROM A DOSE ESCALATION PHASE 1/2 CLINICAL TRIAL
Authors: Samuel Goldlust, Burt Nabors, J. Paul Duic, Nimish Mohile, Tara Benkers, Sigmund Hsu, Sandra Silberman, Samuel Singer, Mayank Rao, George Farmer
Journal: Neuro-Oncology (2016)

Microtubule inhibitors have demonstrated efficacy in preclinical models of glioblastoma (GBM), however, clinical benefit is compromised by poor blood-brain barrier (BBB) accumulation. TPI 287, a third-generation taxane designed to evade mechanisms of P-glycoprotein mediated efflux, readily penetrates the BBB, thereby overcoming this limitation. Near-final results following further follow-up of the recently completed dose escalation stage of a Phase 1/2 trial evaluating TPI 287 plus bevacizumab (BEV) are reported here. GBM patients at first or second relapse after standard therapy and without prior exposure to anti-angiogenic agents were eligible for enrollment. Based on a traditional 3+3 design, TPI 287 was administered every 3 weeks via IV infusion and BEV was administered at 10 mg/kg every 2 weeks. MRIs were obtained every six weeks with response assessed via RANO. Twenty-four patients were enrolled in seven TPI 287 dose-escalation cohorts (140–220 mg/m2). No DLTs were reported and myelosuppression (n=3) was the only drug-related grade 3/4 adverse event. Ten patients achieved SD and 1 patient showed progressive disease at first scan. Among 20 patients evaluable for response, ORR was 60% (12/20; 3 complete, 9 partial). The median and 6-month PFS were 5.5 mo. [95% C.I. 4.1–8.2] and 40%, respectively. At time of abstract submission, median and 1-year OS were 12.9 mo. [95% C.I. 10.9–17.9] and 60%, respectively, after 20.2 mo. median follow-up. TPI 287 plus BEV is safe and well tolerated at doses up to 220 mg/m2. Survival results compare favorably with historical controls. Final safety and efficacy results from the dose-escalation portion of this trial will be presented. Advancement to the Phase 2 dose-expansion stage of the trial is underway.